TCTMD’s Top 10 Most Popular Stories for August 2019
FDA news on TAVR for low-risk patients, paclitaxel PAD devices, and baroreflex activation in heart failure dominated this month.
Approvals, updates, and alerts from the US Food and Drug Administration made up nearly half of our top 10 stories this month, covering everything from TAVR’s low-risk expansion to the approval of the Barostim Neo baroreflex activation therapy device (CVRx) in advanced heart failure. Also making the list was a study on acute stent thrombosis with the Synergy stent (Boston Scientific), a feature story on structural heart fellowship programs, and the second in our “Off Script” series of first-person physician blogs, this one a defense of selfies and social media in medicine.
Both Evolut R and Evolut PRO (Medtronic), as well Sapien 3 (Edwards Lifesciences), received the expanded indication in the eagerly awaited announcement.
Does the abluminal surface, bioresorbable polymer, or patients’ risk profile explain this? One expert remains skeptical.
The new letter to providers confirms that manufacturers will modify labeling to address the mortality signal.
The allure of TAVR and left atrial appendage closure sways many trainees to sign on for an extra year, but programs are varied and jobs are few.
The Barostim Neo system improved quality of life and exercise capacity in the pivotal BeAT-HF trial.
Topline results show the primary endpoint was met in this phase III trial, which included patients with and without diabetes.
Less complete revascularization of the lateral wall likely contributes to higher mortality with off-pump CABG, say experts.
No products are being pulled from the market; instead, users are told to deploy the valve using slow and continuous pressures.
The scientific advisory zeros in on triglyceride effects and on newer prescription-strength products, as studied in REDUCE-IT.
Kardashians, move over. Twitter is a vibrant community where physicians can connect, discuss, and collaborate with global peers.